Research Article
Panoramic Radiography Features of Medication-Related Osteonecrosis of the Jaws (MRONJ)
Table 2
Pharmacologic variables (n = 150 subjects).
| | Variables | Outcome |
| | Zoledronate (n, (%)) | 103 (68.7%) | | Length of therapy (months, ±SD) | 21.2 ± 10.1 | | Cumulative dose (mg, ±SD) | 84.1 ± 39.4 | | Alendronate (n, (%)) | 31 (20.7%) | | Length of therapy (weeks, ±SD) | 499.4 ± 313.2 | | Cumulative dose (mg, ±SD) | 25,976.8 ± 13,218.9 | | Denosumab (n, (%)) | 9 (6%) | | Length of therapy (months) | 11.4 ± 6.4 | | Cumulative dose (mg, ±SD) | 1,271.1 ± 688.4 | | Ibandronate (n, (%)) | 6 (4%) | | Length of therapy (months) | 83 ± 64.7 | | Cumulative dose (mg, ±SD) | 12,450 ± 970 | | Risedronate (n, (%)) | 1 (0.6%) | | Length of therapy (day) | 100 | | Cumulative dose (mg, ±SD) | 500 |
|
|
